Literature DB >> 9625504

Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy.

M De Jong1, B F Bernard, E De Bruin, A Van Gameren, W H Bakker, T J Visser, H R Mäcke, E P Krenning.   

Abstract

We compared the internalization of [90Y-DOTA0,Tyr3]octreotide and [111In-DOTA0,Tyr3]octreotide with that of [125I-Tyr3]octreotide and [111In-DTPA0]octreotide in the subtype 2 somatostatin receptor (sst2)-positive rat pancreatic tumour cell lines CA20948 and AR42J and in the somatostatin receptor-negative human anaplastic thyroid tumour cell line ARO. We demonstrated that [111In-DTPA0]octreotide, [90Y-DOTA0,Tyr3]octreotide and [111In-DOTA0,Tyr3]octreotide are internalized by a receptor-specific, time- and temperature-dependent process. The amount of [90Y-DOTA0,Tyr3]octreotide internalized was higher than that of [111In-DOTA0,Tyr3]octreotide and [111In-DTPA0]octreotide.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9625504     DOI： 10.1097/00006231-199803000-00013

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN： 0143-3636            Impact factor:   1.690


  18 in total

Review 1.  Radionuclide therapy beyond radioiodine.

Authors:  Michael Gabriel
Journal:  Wien Med Wochenschr       Date:  2012-07-20

2.  Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.

Authors:  Dongyoul Lee; Mengshi Li; Bryan Bednarz; Michael K Schultz
Journal:  Radiat Res       Date:  2018-06-26       Impact factor: 2.841

3.  Inhomogeneous activity distribution of 177Lu-DOTA0-Tyr3-octreotate and effects on somatostatin receptor expression in human carcinoid GOT1 tumors in nude mice.

Authors:  Jenny Oddstig; Peter Bernhardt; Helena Lizana; Ola Nilsson; Håkan Ahlman; Lars Kölby; Eva Forssell-Aronsson
Journal:  Tumour Biol       Date:  2011-11-23

4.  99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study.

Authors:  Clemens Decristoforo; Theodosia Maina; Berthold Nock; Michael Gabriel; Paul Cordopatis; Roy Moncayo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-04       Impact factor: 9.236

5.  Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours.

Authors:  M de Visser; H F Bernard; J L Erion; M A Schmidt; A Srinivasan; B Waser; J C Reubi; E P Krenning; M de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-08       Impact factor: 9.236

6.  Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research.

Authors:  Carolyn J Anderson; Riccardo Ferdani
Journal:  Cancer Biother Radiopharm       Date:  2009-08       Impact factor: 3.099

7.  Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET).

Authors:  Monica Shokeen; Carolyn J Anderson
Journal:  Acc Chem Res       Date:  2009-07-21       Impact factor: 22.384

8.  Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases.

Authors:  Georgios S Limouris; Achilles Chatziioannou; Dimitrios Kontogeorgakos; Dimitrios Mourikis; Maria Lyra; Panagiotis Dimitriou; Anastasia Stavraka; Athanassios Gouliamos; Lambros Vlahos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-07       Impact factor: 9.236

Review 9.  Peptide receptor therapies in neuroendocrine tumors.

Authors:  L Bodei; D Ferone; C M Grana; M Cremonesi; A Signore; R A Dierckx; G Paganelli
Journal:  J Endocrinol Invest       Date:  2009-04       Impact factor: 4.256

10.  Linker effects on biological properties of 111In-labeled DTPA conjugates of a cyclic RGDfK dimer.

Authors:  Bing Jia; Zhaofei Liu; Jiyun Shi; Zilin Yu; Zhi Yang; Huiyun Zhao; Zhengjie He; Shuang Liu; Fan Wang
Journal:  Bioconjug Chem       Date:  2007-12-11       Impact factor: 4.774
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.